Colorectal cancer screening: Virginia health districts in greatest need and the impact of insurance coverage on fecal occult blood testing and endoscopy
Advisor: Resa Jones, Ph.D., MPH
Background: Colorectal cancer (CRC) is the second most common
cancer in the United States. CRC deaths can be prevented with screening; however,
the uninsured are often less likely to have recommended screening. Moreover,
it is not clear where the greatest areas of CRC screening need are within Virginia.
Objectives: This study aims to compare the prevalence of
CRC screening among Virginia adults ages 50 and older by insurance status
and health district. Also, this study aims to assist the Every Women’s
Life (EWL) program by determining health districts in greatest need of CRC
screening.
Methods: Cross-sectional data from the 2006 Behavioral Risk
Factor Surveillance System (BRFSS) survey were analyzed. Descriptive statistics
were generated. Weighted multiple regression was used to assess the association
between insurance coverage and CRC screening prevalence among Virginia adults
ages 50 and older (N=3,030) as well as CRC screening prevalence by health district.
Also, arcGIS was used to map screening prevalence by health district.
Results: After adjustment, men with insurance were more likely
to have ever had fecal occult blood test (FOBT) or endoscopy (p<.01) compared
to those without insurance and they were more likely to have either modality
according to recommended guidelines (p=.0004). Women with insurance were not
statistically more likely to have CRC screening than those without insurance.
CRC screening per recommendations for men was lowest in the Central Virginia
Health District (19.39%) whereas overall adherence for women was lowest in
the Cumberland Plateau Health District (38.65%).
Conclusion: Insurance coverage seems to impact whether men
receive CRC screening, but, has no association with screening for Virginia
women. Health districts in greatest need of CRC screening differ by gender.
Overall, EWL screening efforts should be targeted to specific health districts
in southwestern and central Virginia as well as along the eastern shore.



















